| New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone ... - Gamut News (press release) |
|
|
Gamut News (press release) In the US there are more than 26 million patients with CKD, and more than 450000 patients with end-stage renal disease (ESRD). Bardoxolone methyl is a novel, first-in-class antioxidant inflammation modulator (AIM). Bardoxolone activates the Nrf2 |